ZKHF 001
Alternative Names: ZKHF-001Latest Information Update: 01 Feb 2023
At a glance
- Originator Zhaoke Pharmaceutical (Hefei)
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiovascular disorders
Most Recent Events
- 01 Feb 2023 Phase II development for Cardiovascular disorders is ongoing in China (unspecified route) (Lee's pharmaceutical pipeline, February 2022)
- 10 Dec 2020 Phase-II clinical trials in Cardiovascular disorders in China (unspecified route) prior to December 2020 (Lee's pharmaceutical pipeline, December 2020)